Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus

作者全名："Chen, Ruifeng; Li, Hu; Zhu, Wuyang; Cheng, Hongbin; Li, Yu; Li, Xiaomei; Li, Faliang; Liu, Xiaoqiang; Hu, Shixiong; Yan, Baigang; Zheng, Yishan; Zuo, Yongbo; Dong, Guanmu; Li, Xiangming"

作者地址："[Chen, Ruifeng] Gen Hosp Chinese Peoples Liberat Army, Dept Emergency Med, Med Ctr 6, Beijing, Peoples R China; [Li, Hu] China Capital Med Univ, Dept Emergency Med, Beijing Luhe Hosp, Beijing, Peoples R China; [Zhu, Wuyang] Rabies Ward, Inst Viral Dis Control & Prevent, China Ctr Dis Control & Prevent, Beijing, Peoples R China; [Cheng, Hongbin] Forth Cent Hosp Tianjin, Dept Emergency Med, Tianjin, Peoples R China; [Li, Xiangming] China Ctr Dis Control & Prevent, Div Infect Dis Management, Beijing, Peoples R China; [Li, Yu] Inst Immunizat, Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China; [Li, Xiaomei] Zhengzhou Univ, Dept Dis Control, Affiliated Hosp 5, Henan, Peoples R China; [Li, Faliang] Yunnan Ctr Dis Control & Prevent, Vaccine Clin Res Ctr, Yunnan, Peoples R China; [Liu, Xiaoqiang] Hunan Prov Ctr Dis Control & Prevent, Hunan, Peoples R China; [Hu, Shixiong] Chongqing Med Univ, Dept Aid 1, Affiliated Hosp 3, Sichuan, Peoples R China; [Yan, Baigang] Nanjing Second Hosp, Dept Crit Care Med, Jangsu, Peoples R China; [Zheng, Yishan] Beijing Haidian Hosp, Dept Emergency Surg, Emergency Phys Branch Chinese Med Doctor Assoc, Beijing, Peoples R China; [Zuo, Yongbo] Natl Inst Food & Drug Control, Beijing, Peoples R China; [Dong, Guanmu] China Assoc Vaccines, Beijing, Peoples R China; [Dong, Guanmu] Arbovirus Vaccine Room China Inst Food & Drug Cont, Biomed Ind Base, 29 East Area 31 (West Area),Huatuo Rd, Beijing 102629, Peoples R China"

通信作者："Dong, GM (通讯作者)，Arbovirus Vaccine Room China Inst Food & Drug Cont, Biomed Ind Base, 29 East Area 31 (West Area),Huatuo Rd, Beijing 102629, Peoples R China."

来源：EXPERT OPINION ON DRUG SAFETY

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001024186700001

JCR分区：Q2

影响因子：3

年份：2023

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：Anti-rabies monoclonal antibody; ormutivimab; clinical application; consensus standardizes in China; rabies; post-exposure prophylaxis

摘要："Background: There are no local or international guidelines or consensus on the use of mAbs against the rabies virus. Research design and methods: An expert group in the field of rabies prevention and control formulated the consensus presented in this paper. Results: Class III exposed persons to rabies for the first time; Identify type II exposed persons with immune deficiency; those who are first exposed to Class II and re-exposed to Class III within 7 days. They can use ormutivimab injection after completing the PEP wound treatment. In the case of injection restrictions or a wound that is difficult to detect, it is recommended that the entire Ormutivimab dose be infiltrated close to the wound. For severe multi-wound bites, the recommended dosage of ormutivimab is 20 IU/kg. If the recommended dose cannot meet all of the wound infiltration requirements, appropriate dilution can be conducted at a dilution ratio of 3 similar to 5 times. If the requirements for infiltration cannot be met after dilution, it is recommended that the dosage be increased with caution (maximum dosage, 40 IU/kg). The use of Ormutivimab is safe and effective without any contraindications by all age groups. Conclusions: This consensus standardizes clinical use of Ormutivimab, improves post-exposure prophylaxis of rabies in China, reduces infection rate."

基金机构：　

基金资助正文：